Are sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) associated with reduced cardiovascular risk in patients with type 2 diabetes and concomitant nonalcoholic fatty liver disease (NAFLD)? The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.